Nanocurcumin is superior to native curcumin in preventing degenerative changes in Experimental Cerebral Malaria

Abstract

Curcumin has many pharmacological activities despite its poor bioavailability and in vivo stability. Here, we show that a nanoformulated curcumin (PLGA-curcumin) has better therapeutic index than native curcumin in preventing the onset of neurological symptoms and delaying the death of mice in experimental cerebral malaria. Oral PLGA-curcumin was at least as effective as native curcumin at a 15-fold lower concentration in preventing the breakdown of blood-brain barrier and inhibition of brain mRNAs for inflammatory cytokines, chemokine receptor CXCR3 and its ligand CXCL10, with an increase in the anti-inflammatory cytokine IL-10. This was also reflected in serum cytokine and chemokine levels. At equivalent concentrations, a single oral dose of PLGA-curcumin was more effective in inhibiting serum IFNγ levels and enhancing IL-10 levels than native curcumin. Even at low concentrations, PLGA-curcumin was superior to native curcumin in inhibiting the sequestration of parasitized-RBCs and CD8+ T cells in the brain. A single oral dose of 5 mg PLGA-curcumin containing 350 μg of curcumin resulted in 3–4 fold higher concentration and prolonged presence of curcumin in the brain than that obtained with 5 mg of native curcumin, indicating better bioavailability of PLGA-curcumin. PLGA-curcumin has potential as an adjunct drug to treat human cerebral malaria.

Hepato therapeutic Efficacy of Native Curcumim and Nano –curcumin : A Novel Therapy Against Hyperthyroidism Induced Liver Oxidative and Inflammatory Damage in Rats

“…Our findings are consistent with a number of studies where encapsulation of curcumin in various nanoformulations has been shown to improve its effects on different cellular parameters in animal and cell based systems by enhancing stability and bioavailability. For example, oral feeding of PLGA encapsulated curcumin exhibited increased bioavailability through enhanced retention in the brain and prevented the breakdown of blood-brain barrier [9]. Importantly, the improved performance of nanocurcumin is suggested to be mediated by decreased inflammatory cytokines, chemokine receptor and increased anti-inflammatory cytokines [9].…”

“…For example, oral feeding of PLGA encapsulated curcumin exhibited increased bioavailability through enhanced retention in the brain and prevented the breakdown of blood-brain barrier [9]. Importantly, the improved performance of nanocurcumin is suggested to be mediated by decreased inflammatory cytokines, chemokine receptor and increased anti-inflammatory cytokines [9]. Similarly, enhanced antiangiogenic effects of curcumin including inhibition of HUVEC proliferation, migration, invasion, and tube formation were noticed in human liver cancer SMMC 7721 cells treated with curcumin encapsulated in pHsensitive polymeric nanoparticles [22].…”

“…To circumvent these obstacles, some studies have focused attention on the utilization of nanomaterials to encapsulate curcumin to enhance its bioavailability. For example, nanocurcumin has been shown to be superior to curcumin in preventing degenerative changes in DOI: http://dx.doi.org/10.22192/ijarbs.2017.04.12.009 experimental cerebral malaria [9]. Nanocurcumin was found to be more effective in its antiproliferative properties compared to native curcumin in MDA breast cancer cell lines [10].…”

The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties

“…The curcuminoid complex, found in the rhizome of turmeric (2.5-6%), contains CUR, demethoxycurcumin, and bis-demethoxycurcumin [11].…”

Curcumin Regulates the r(CGG)exp RNA Hairpin Structure and Ameliorate Defects in Fragile X-Associated Tremor Ataxia Syndrome

“…Henceforth, Curcumin reach brain in biological effective concentration and ameliorate neurodegeneration (Begum et al, 2008;Schiborr et al, 2010). To further increase the bioavailability of Curcumin, researchers have been designed different nanoparticles (Nanocurcumin) to enhance its pharmacological activity (Barbara et al, 2017;Dende et al, 2017). In conclusion, our data provide evidence that Curcumin could be used for the therapeutics of CGG associated diseases FXTAS and FXPOI.…”